Two Sigma Investments LP Buys 84,375 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Two Sigma Investments LP increased its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 166.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 135,084 shares of the company's stock after acquiring an additional 84,375 shares during the quarter. Two Sigma Investments LP owned approximately 0.18% of Nurix Therapeutics worth $2,545,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. US Bancorp DE increased its position in shares of Nurix Therapeutics by 144.7% during the 4th quarter. US Bancorp DE now owns 1,424 shares of the company's stock valued at $27,000 after purchasing an additional 842 shares during the last quarter. Aquatic Capital Management LLC bought a new position in Nurix Therapeutics during the fourth quarter valued at about $87,000. Summit Investment Advisors Inc. increased its holdings in Nurix Therapeutics by 13.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock worth $138,000 after buying an additional 877 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in Nurix Therapeutics in the fourth quarter worth about $164,000. Finally, Nomura Holdings Inc. purchased a new position in Nurix Therapeutics in the fourth quarter valued at about $198,000.

Insider Activity at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 6,198 shares of the company's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $11.33, for a total transaction of $70,223.34. Following the completion of the sale, the chief financial officer now owns 33,724 shares of the company's stock, valued at $382,092.92. This represents a 15.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Gwenn Hansen sold 3,377 shares of the stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $38,835.50. Following the completion of the transaction, the insider now owns 61,516 shares in the company, valued at $707,434. The trade was a 5.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,013 shares of company stock valued at $137,096 in the last 90 days. Corporate insiders own 7.40% of the company's stock.

Nurix Therapeutics Trading Up 0.3%

Shares of NRIX stock traded up $0.04 during trading hours on Wednesday, reaching $12.12. The company's stock had a trading volume of 120,786 shares, compared to its average volume of 877,767. Nurix Therapeutics, Inc. has a one year low of $8.18 and a one year high of $29.56. The stock has a market capitalization of $923.68 million, a P/E ratio of -4.22 and a beta of 2.23. The firm's fifty day simple moving average is $10.33 and its 200 day simple moving average is $15.54.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.05. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. The firm had revenue of $18.45 million during the quarter, compared to analyst estimates of $12.78 million. During the same quarter in the prior year, the company earned ($0.76) EPS. As a group, equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on NRIX shares. Wells Fargo & Company lowered their price target on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 9th. Leerink Partnrs upgraded Nurix Therapeutics to a "hold" rating in a research report on Monday, March 17th. Needham & Company LLC reissued a "buy" rating and set a $27.00 price objective on shares of Nurix Therapeutics in a report on Tuesday, April 29th. HC Wainwright reissued a "buy" rating and issued a $36.00 price target on shares of Nurix Therapeutics in a report on Wednesday, April 2nd. Finally, Stifel Nicolaus cut their target price on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $30.44.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.